Anixa Biosciences began animal Testing of Covid-19 therapeutic candidates
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
On Feb. 16, 2021, Moderna provided a supply update for their COVID-19 Vaccine in the United States, reporting…
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
On Feb. 15, 2021, the WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving…
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
On Feb. 13, 2021, the University of Oxford, together with three partner sites in London, Southampton and Bristol,…
On Feb. 12, 2021, Moderna announced that the Canadian Government had increased its confirmed order commitment by 4…
On Feb. 12, 2021, BioNTech announced that the U.S. government had exercised its option for an additional 100…
On Feb. 12, 2021, the NIH announced that enrollment had begun to test additional investigational drugs in the…
On Feb. 11, 2021, Moderna announced that the Qatar Ministry of Public Health had issued an emergency use…
On Feb. 11, 2021, Moderna announced that the U.S. government had purchased an additional 100 million doses of…
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
On Feb. 9, 2021, Moderna announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government…
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they have completed the development and initiated the commercial…
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
On Feb. 5, 2021, CureVac announced that it had entered a collaboration with the UK Government to develop…
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxford’s…
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
On Feb. 3, 2021, GlaxoSmithKline and CureVac announced a new タ150m collaboration, building on their existing relationship, to…
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…